elranatamab
pfizer
['8014', 'magnetismm-1', 'multiplemyeloma', 'pfizer']
see updated results from the ongoing first-in-human phase 1 magnetismm-1 trial characterizing the safety, efficacy, pharmacokinetics, &amp; pharmacodynamics of a bcma-cd3 bispecific antibody in patients with r/r #multiplemyeloma at #asco22 8014 
Dedicated to communicating emerging science from Pfizer Oncology. Please see our community guidelines: https://t.co/MU3blmItSZ